ArticleJournal for immunotherapy of cancer2023

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.

Darien E Reed-Perino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.